A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Primary Sclerosing Cholangitis

In brief

The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Sclerosing Cholangitis.

Key facts

Study ID

NCT02704364

Run by

NGM Biopharmaceuticals, Inc

People needed

62

Starts

2016-03-01

Expected to finish

2017-06-01

Last updated by the study team

2025-06-17

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of PSC

You may not qualify if…

• Clinically significant acute or chronic liver disease of an etiology other than PSC
• Secondary or IgG4 related sclerosing cholangitis

Where it is running

• NGM Clinical Study Site 118 — Sacramento, California, United States
• NGM Clinical Study Site 112 — San Clemente, California, United States
• NGM Clinical Study Site 127 — San Francisco, California, United States
• NGM Clinical Study Site 106 — Aurora, Colorado, United States
• NGM Clinical Study Site 115 — Washington D.C., District of Columbia, United States
• NGM Clinical Study Site 110 — Gainesville, Florida, United States
• NGM Clinical Study Site 124 — Lakewood Rch, Florida, United States
• NGM Clinical Study Site 105 — Miami, Florida, United States
• NGM Clinical Study Site 109 — Indianapolis, Indiana, United States
• NGM Clinical Study Site 104 — Detroit, Michigan, United States
• NGM Clinical Study Site 102 — Kansas City, Missouri, United States
• NGM Clinical Study Site 107 — St Louis, Missouri, United States
• NGM Clinical Study Site 103 — New York, New York, United States
• NGM Clinical Study Site 116 — Durham, North Carolina, United States
• NGM Clinical Study Site 120 — Cincinnati, Ohio, United States
• NGM Clinical Study Site 114 — Nashville, Tennessee, United States
• NGM Clinical Study Site 113 — Dallas, Texas, United States
• NGM Clinical Study Site 117 — Dallas, Texas, United States
• NGM Clinical Study Site 119 — Houston, Texas, United States
• NGM Clinical Study Site 125 — Southlake, Texas, United States
• NGM Clinical Study Site 111 — Charlottesville, Virginia, United States
• NGM Clinical Study Site 122 — Newport News, Virginia, United States
• NGM Clinical Study Site 101 — Norfolk, Virginia, United States
• NGM Clinical Study Site 121 — Richmond, Virginia, United States
• NGM Clinical Study Site 108 — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.